keyword
MENU ▼
Read by QxMD icon Read
search

L-DOPA rodent

keyword
https://www.readbyqxmd.com/read/28288194/the-aromatic-amino-acid-hydroxylase-genes-aah1-and-aah2-in-toxoplasma-gondii-contribute-to-transmission-in-the-cat
#1
Zi T Wang, Shiv K Verma, Jitender P Dubey, L David Sibley
The Toxoplasma gondii genome contains two aromatic amino acid hydroxylase genes, AAH1 and AAH2, which encode proteins that produce L-DOPA, which can serve as a precursor of catecholamine neurotransmitters. It has been suggested that this pathway elevates host dopamine levels thus making infected rodents less fearful of their definitive Felidae hosts. However, L-DOPA is also a structural precursor of melanins, secondary quinones, and dityrosine protein crosslinks, which are produced by many species. For example, dityrosine crosslinks are abundant in the oocyst walls of Eimeria and T...
March 13, 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28286180/dysregulation-of-bet-proteins-in-levodopa-induced-dyskinesia
#2
David A Figge, David G Standaert
Levodopa (L-DOPA) remains the most effective pharmacological treatment for Parkinson Disease (PD) but its use is limited by the development of debilitating drug-related side effects, particularly L-DOPA induced dyskinesia (LID). LID is a consequence of long-term L-DOPA use, and in model systems is characterized by a "priming effect", whereby initial administrations of L-DOPA trigger a sensitized biochemical and transcriptional response upon subsequent dopaminergic stimulation. Preliminary studies into the mechanisms underlying this cellular memory have indicated an important role for epigenetic change but many of the downstream mechanisms remain unknown...
March 9, 2017: Neurobiology of Disease
https://www.readbyqxmd.com/read/28268703/an-implantable-microelectrode-array-for-dopamine-and-electrophysiological-recordings-in-response-to-l-dopa-therapy-for-parkinson-s-disease
#3
Song Zhang, Yilin Song, Jun Jia, Guihua Xiao, Lili Yang, Min Sun, Mixia Wang, Xinxia Cai
Dual-mode multielectrode recordings have become routine in rodent neuroscience research. However, robust and reliable application of acute, multielectrode recording methods in brain especially for in vivo research remains a challenge. In patients with Parkinson's disease (PD), the efficacy of L-dopa therapy depends on its ability to restore Dopamine (DA) neurotransmission in the striatum. In this paper, We describe a low cost thin film 16 sites implantable microelectrode array (MEA) chip fabricated by standard lithography technology for in vivo test...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28226891/an-implantable-microelectrode-array-for-dopamine-and-electrophysiological-recordings-in-response-to-l-dopa-therapy-for-parkinson-s-disease
#4
Song Zhang, Yilin Song, Jun Jia, Guihua Xiao, Lili Yang, Min Sun, Mixia Wang, Xinxia Cai, Song Zhang, Yilin Song, Jun Jia, Guihua Xiao, Lili Yang, Min Sun, Mixia Wang, Xinxia Cai, Xinxia Cai, Lili Yang, Guihua Xiao, Mixia Wang, Yilin Song, Song Zhang, Min Sun, Jun Jia
Dual-mode multielectrode recordings have become routine in rodent neuroscience research. However, robust and reliable application of acute, multielectrode recording methods in brain especially for in vivo research remains a challenge. In patients with Parkinson's disease (PD), the efficacy of L-dopa therapy depends on its ability to restore Dopamine (DA) neurotransmission in the striatum. In this paper, We describe a low cost thin film 16 sites implantable microelectrode array (MEA) chip fabricated by standard lithography technology for in vivo test...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28112685/chemogenetic-stimulation-of-striatal-projection-neurons-modulates-responses-to-parkinson-s-disease-therapy
#5
Cristina Alcacer, Laura Andreoli, Irene Sebastianutto, Johan Jakobsson, Tim Fieblinger, Maria Angela Cenci
Parkinson's disease (PD) patients experience loss of normal motor function (hypokinesia), but can develop uncontrollable movements known as dyskinesia upon treatment with L-DOPA. Poverty or excess of movement in PD has been attributed to overactivity of striatal projection neurons forming either the indirect (iSPNs) or the direct (dSPNs) pathway, respectively. Here, we investigated the two pathways' contribution to different motor features using SPN type-specific chemogenetic stimulation in rodent models of PD (PD mice) and L-DOPA-induced dyskinesia (LID mice)...
February 1, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/27764702/contribution-of-the-nitric-oxide-donor-molsidomine-and-the-antiparkinsonian-drug-l-dopa-to-the-modulation-of-the-blood-pressure-in-unilaterally-6-ohda-lesioned-rats
#6
Elżbieta Lorenc-Koci, Anna Czarnecka, Kinga Kamińska, Joanna Knutelska, Małgorzata Zygmunt, Magdalena Dudek
BACKGROUND: Interaction between dopaminergic and nitrergic neurotransmission in the brain plays a crucial role in the control of motor function and in the regulation of blood pressure (BP). In Parkinson's disease (PD), dopaminergic denervation of the striatum leads to disturbances in the nitrergic system in the basal ganglia. Recently, it has been demonstrated that addition of a low dose of the nitric oxide donor molsidomine to l-DOPA therapy improves dopaminergic neurotransmission in the denervated nigrostriatal system and weakens dyskinesias in rodent models of the disease...
February 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/27733830/cannabidiol-prevents-motor-and-cognitive-impairments-induced-by-reserpine-in-rats
#7
Fernanda F Peres, Raquel Levin, Mayra A Suiama, Mariana C Diana, Douglas A Gouvêa, Valéria Almeida, Camila M Santos, Lisandro Lungato, Antônio W Zuardi, Jaime E C Hallak, José A Crippa, D'Almeida Vânia, Regina H Silva, Vanessa C Abílio
Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27618286/l-dopa-induced-dyskinesia-in-parkinson-s-disease-are-neuroinflammation-and-astrocytes-key-elements
#8
Elaine Del-Bel, Mariza Bortolanza, Maurício Dos-Santos-Pereira, Keila Bariotto, Rita Raisman-Vozari
Inflammation in Parkinson's disease (PD) is a new concept that has gained ground due to the potential of mitigating dopaminergic neuron death by decreasing inflammation. The solution to this question is likely to be complex. We propose here that the significance of inflammation in PD may go beyond the nigral cell death. The pathological process that underlies PD requires years to reach its full extent. A growing body of evidence has been accumulated on the presence of multiple inflammatory signs in the brain of PD patients even in very late stages of the disease...
December 2016: Synapse
https://www.readbyqxmd.com/read/27597526/validation-of-an-improved-scale-for-rating-l-dopa-induced-dyskinesia-in-the-mouse-and-effects-of-specific-dopamine-receptor-antagonists
#9
Irene Sebastianutto, Natallia Maslava, Corey R Hopkins, M Angela Cenci
Rodent models of l-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude...
September 2, 2016: Neurobiology of Disease
https://www.readbyqxmd.com/read/27596273/lack-of-antiparkinsonian-effects-of-systemic-injections-of-the-specific-t-type-calcium-channel-blocker-ml218-in-mptp-treated-monkeys
#10
Adriana Galvan, Annaelle Devergnas, Damien Pittard, Gunasingh Masilamoni, Jocelyn Vuong, J Scott Daniels, Ryan D Morrison, Craig W Lindsley, Thomas Wichmann
Dopaminergic medications ameliorate many of the motor impairments of Parkinson's disease (PD). However, parkinsonism is often only partially reversed by these drugs, and they can have significant side effects. Therefore, a need remains for novel treatments of parkinsonism. Studies in rodents and preliminary clinical evidence have shown that T-type calcium channel (TTCC) antagonists have antiparkinsonian effects. However, most of the available studies utilized nonselective agents. We now evaluated whether systemic injections of the specific TTCC blocker ML218 have antiparkinsonian effects in MPTP-treated parkinsonian Rhesus monkeys...
November 16, 2016: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/27418401/parkinsonian-monkeys-with-prior-levodopa-induced-dyskinesias-followed-by-fetal-dopamine-precursor-grafts-do-not-display-graft-induced-dyskinesias
#11
Jeffrey H Kordower, Angel Vinuela, Yaping Chu, Ole Isacson, D Eugene Redmond
Clinical trials testing the hypothesis that fetal dopamine grafts would provide antiparkinsonian benefit in patients who had already developed side effects from their long-term use of L-dopa revealed, in some cases, the presence of dyskinesias even in the absence of L-dopa. The form, intensity, and frequency of these dyskinesias were quite variable, but their manifestation slowed the clinical development of cell replacement therapies. Rodent models of graft-induced dyskinesias (GIDs) have been proposed, but their accuracy in modeling GIDs has been questioned because they usually require amphetamine for their presentation...
February 15, 2017: Journal of Comparative Neurology
https://www.readbyqxmd.com/read/27378874/subthalamic-and-cortical-local-field-potentials-associated-with-pilocarpine-induced-oral-tremor-in-the-rat
#12
Lauren L Long, Samantha J Podurgiel, Aileen F Haque, Emily L Errante, James J Chrobak, John D Salamone
Tremulous jaw movements (TJMs) are rapid vertical deflections of the lower jaw that resemble chewing but are not directed at any particular stimulus. In rodents, TJMs are induced by neurochemical conditions that parallel those seen in human Parkinsonism, including neurotoxic or pharmacological depletion of striatal dopamine (DA), DA antagonism, and cholinomimetic administration. Moreover, TJMs in rodents can be attenuated by antiparkinsonian agents, including levodopa (L-DOPA), DA agonists, muscarinic antagonists, and adenosine A2A antagonists...
2016: Frontiers in Behavioral Neuroscience
https://www.readbyqxmd.com/read/27307239/dynamic-dna-methylation-regulates-levodopa-induced-dyskinesia
#13
David A Figge, Karen L Eskow Jaunarajs, David G Standaert
UNLABELLED: Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (l-DOPA) exposure in Parkinson disease patients. LID is a consequence of sustained changes in the transcriptional behavior of striatal neurons following dopaminergic stimulation. In neurons, transcriptional regulation through dynamic DNA methylation has been shown pivotal to many long-term behavioral modifications; however, its role in LID has not yet been explored...
June 15, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27283777/l-dopa-treatment-in-mptp-mouse-model-of-parkinson-s-disease-potentiates-homocysteine-accumulation-in-substantia-nigra
#14
Nivedita Bhattacharjee, Muhammed Khairujjaman Mazumder, Rajib Paul, Amarendranath Choudhury, Sabanum Choudhury, Anupom Borah
One of the intermediates of methionine cycle, the homocysteine (Hcy), elevates in plasma of Parkinson's disease (PD) patients undergoing L-DOPA (3,4-dihydroxyphenylalanine) therapy and has been regarded as a risk factor of the disease. Several evidences pointed out that Hcy causes degeneration of dopaminergic neurons. In rodent, elevated level of Hcy in brain or infusion of the same directly into the substantia nigra (SN) potentiates dopaminergic neurodegeneration. However, the influence of L-DOPA therapy on the levels of Hcy in dopamine-rich regions of the brain (striatum and SN) of experimental models of PD is not known...
August 15, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/26903804/striatal-plasticity-in-l-dopa-and-graft-induced-dyskinesia-the-common-link
#15
REVIEW
Daniella Rylander Ottosson, Emma Lane
One of the major symptoms of the neurodegenerative condition Parkinson's disease (PD) is a slowness or loss of voluntary movement, yet frustratingly therapeutic strategies designed to restore movement can result in the development of excessive abnormal movements known as dyskinesia. These dyskinesias commonly develop as a result of pharmacotherapy in the form of L-DOPA administration, but have also been identified following deep brain stimulation (DBS) and intrastriatal cell transplantation. In the case of L-DOPA these movements can be treatment limiting, and whilst they are not long lasting or troubling following DBS, recognition of their development had a near devastating effect on the field of cell transplantation for PD...
2016: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/26871939/antidyskinetic-effect-of-a2a-and-5ht1a-1b-receptor-ligands-in-two-animal-models-of-parkinson-s-disease
#16
Annalisa Pinna, Wai Kin D Ko, Giulia Costa, Elisabetta Tronci, Camino Fidalgo, Nicola Simola, Qin Li, Mojgan Aghazadeh Tabrizi, Erwan Bezard, Manolo Carta, Micaela Morelli
BACKGROUND: The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior. OBJECTIVES: We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress l-dopa-induced dyskinesia, without impairing l-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys...
April 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/26644333/long-term-effect-of-sub-anesthetic-ketamine-in-reducing-l-dopa-induced-dyskinesias-in-a-preclinical-model
#17
Mitchell J Bartlett, Ria M Joseph, Lindsey M LePoidevin, Kate L Parent, Nicholas D Laude, Levi B Lazarus, Michael L Heien, Miguel Estevez, Scott J Sherman, Torsten Falk
Low-dose sub-anesthetic ketamine infusion treatment has led to a long-term reduction of treatment-resistant depression and posttraumatic stress disorder (PTSD) symptom severity, as well as reduction of chronic pain states, including migraine headaches. Ketamine also is known to change oscillatory electric brain activity. One commonality between migraine headaches, depression, PTSD, Parkinson's disease (PD) and l-DOPA-induced dyskinesias (LID) is hypersynchrony of electric activity in the brain, including the basal ganglia...
January 26, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/26586558/effects-of-l-dopa-priming-on-cortical-high-beta-and-high-gamma-oscillatory-activity-in-a-rodent-model-of-parkinson-s-disease
#18
Kristin B Dupre, Ana V Cruz, Alex J McCoy, Claire Delaville, Colin M Gerber, Katherine W Eyring, Judith R Walters
Prolonged L-dopa treatment in Parkinson's disease (PD) often leads to the expression of abnormal involuntary movements known as L-dopa-induced dyskinesia. Recently, dramatic 80 Hz oscillatory local field potential (LFP) activity within the primary motor cortex has been linked to dyskinetic symptoms in a rodent model of PD and attributed to stimulation of cortical dopamine D1 receptors. To characterize the relationship between high gamma (70-110 Hz) cortical activity and the development of L-dopa-induced dyskinesia, cortical LFP and spike signals were recorded in hemiparkinsonian rats treated with L-dopa for 7 days, and dyskinesia was quantified using the abnormal involuntary movements (AIMs) scale...
February 2016: Neurobiology of Disease
https://www.readbyqxmd.com/read/26475156/perinatal-6-hydroxydopamine-to-produce-a-lifelong-model-of-severe-parkinson-s-disease
#19
John P Kostrzewa, Rose Anna Kostrzewa, Richard M Kostrzewa, Ryszard Brus, Przemysław Nowak
The classic rodent model of Parkinson's disease (PD) is produced by unilateral lesioning of pars compacta substantia nigra (SNpc) in adult rats, producing unilateral motor deficits which can be assessed by dopamine (DA) D2 receptor (D2-R) agonist induction of measurable unilateral rotations. Bilateral SNpc lesions in adult rats produce life-threatening aphagia, adipsia, and severe motor disability resembling paralysis-a PD model that is so compromised that it is seldom used. Described in this paper is a PD rodent model in which there is bilateral 99 % loss of striatal dopaminergic innervation, produced by bilateral intracerebroventricular or intracisternal 6-hydroxydopamine (6-OHDA) administration to perinatal rats...
October 17, 2015: Current Topics in Behavioral Neurosciences
https://www.readbyqxmd.com/read/26472532/nicotine-and-nicotinic-receptor-drugs-potential-for-parkinson-s-disease-and-drug-induced-movement-disorders
#20
REVIEW
Maryka Quik, Tanuja Bordia, Danhui Zhang, Xiomara A Perez
Parkinson's disease is a progressive neurodegenerative disorder associated with tremor, rigidity, and bradykinesia, as well as nonmotor symptoms including autonomic impairments, olfactory dysfunction, sleep disturbances, depression, and dementia. Although the major neurological deficit is a loss of nigrostriatal dopaminergic neurons, multiple neurotransmitters systems are compromised in Parkinson's disease. Consistent with this observation, dopamine replacement therapy dramatically improves Parkinson's disease motor symptoms...
2015: International Review of Neurobiology
keyword
keyword
55861
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"